4598 Stock Overview
Develops anticancer drugs. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Delta-Fly Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥572.00 |
| 52 Week High | JP¥903.00 |
| 52 Week Low | JP¥445.00 |
| Beta | 0.0049 |
| 1 Month Change | 5.73% |
| 3 Month Change | -10.34% |
| 1 Year Change | -31.25% |
| 3 Year Change | -68.74% |
| 5 Year Change | -61.25% |
| Change since IPO | -88.76% |
Recent News & Updates
Shareholder Returns
| 4598 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | 6.3% | 0.3% | -1.0% |
| 1Y | -31.3% | 19.8% | 6.1% |
Return vs Industry: 4598 underperformed the JP Biotechs industry which returned 19.8% over the past year.
Return vs Market: 4598 underperformed the JP Market which returned 6.1% over the past year.
Price Volatility
| 4598 volatility | |
|---|---|
| 4598 Average Weekly Movement | 11.8% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in JP Market | 7.5% |
| 10% least volatile stocks in JP Market | 1.8% |
Stable Share Price: 4598's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4598's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 13 | Kiyoshi Eshima | www.delta-flypharma.co.jp |
Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase III clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase I/II clinical trials for the treatment of solid cancer; DFP-11207, which has completed phase I clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, which is in preclinical trial to treat gastric/ovarian cancer. Delta-Fly Pharma, Inc. was incorporated in 2010 and is headquartered in Tokushima, Japan.
Delta-Fly Pharma, Inc. Fundamentals Summary
| 4598 fundamental statistics | |
|---|---|
| Market cap | JP¥5.66b |
| Earnings (TTM) | -JP¥1.75b |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.2x
P/E RatioIs 4598 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4598 income statement (TTM) | |
|---|---|
| Revenue | JP¥0 |
| Cost of Revenue | JP¥0 |
| Gross Profit | JP¥0 |
| Other Expenses | JP¥1.75b |
| Earnings | -JP¥1.75b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 14, 2025
| Earnings per share (EPS) | -179.45 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 4598 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/07 11:25 |
| End of Day Share Price | 2025/02/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Delta-Fly Pharma, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kiyokazu Yamazaki | Ichiyoshi Research Institute Inc. |